---
title: "Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Dosing and administration questions"
description: "Dosing and administration questions on Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing and Treatment combinations. Questions: What is the recommended Ibrance dose and schedule? Do premenopausal women taking Ibrance need an LHRH agonist? 2 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Dosing and administration questions

Manufacturer: Pfizer Laboratories Div Pfizer Inc  
Prescribing information: [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921), [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191)

Dosing and administration questions that apply to every indication of Ibrance are on [Ibrance (palbociclib), all indications: Dosing and administration](https://www.evicenter.com/medical-information/ibrance/dosing-and-administration).

## Dosing

<a id="ibrance-dose"></a>

### What is the recommended Ibrance dose and schedule?

> “The recommended dosage of IBRANCE is a 125 mg tablet taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. IBRANCE tablet may be taken with or without food [see Clinical Pharmacology (12.3)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20recommended%20dosage%20of%20IBRANCE,food%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “The recommended dosage of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. IBRANCE capsule should be taken with food [see Clinical Pharmacology (12.3)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191#:~:text=The%20recommended%20dosage%20of%20IBRANCE,food%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “Dosage strengths are the same for both formulations. IBRANCE is available in 125 mg, 100 mg, and 75 mg doses. Both tablets and capsules follow the same treatment schedule—take 1 dose of IBRANCE once daily for 3 weeks on and 1 week off.<sup>1,2</sup>”

Source: [IBRANCE: Tablets & Capsules, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/tablets-capsules#:~:text=Dosage%20strengths%20are%20the%20same,weeks%20on%20and%201%20week)

> “Refer to the Prescribing Information for recommended dosage for endocrine therapy administered in combination with IBRANCE.”

Source: [IBRANCE: Dosing & Administration, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/administration#:~:text=Refer%20to%20the%20Prescribing%20Information,administered%20in%20combination%20with%20IBRANCE.)

Note: The first passage is from the IBRANCE tablets Prescribing Information, the second from the IBRANCE capsules Prescribing Information, the third from the tablets and capsules page, and the fourth from the dosing page of the Ibrance HCP site, under HR+/HER2- mBC.

## Treatment combinations

<a id="ibrance-premenopausal-lhrh"></a>

### Do premenopausal women taking Ibrance need an LHRH agonist?

> “Pre/perimenopausal women treated with IBRANCE should also be treated with LHRH agonists [see Dosage and Administration (2.1)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Pre%2Fperimenopausal%20women%20treated%20with%20IBRANCE,%5Bsee%20Dosage%20and%20Administration%20%282.1%29%5D.)

> “Pre/perimenopausal women were enrolled in the study and received the LHRH agonist goserelin for at least 4 weeks prior to and for the duration of PALOMA-3.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Pre%2Fperimenopausal%20women%20were%20enrolled%20in,for%20the%20duration%20of%20PALOMA%2D3.)

## Related pages
- [Medical information: Ibrance (palbociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
